Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

A randomized Phase 2b study of GVAX pancreas and CRS-207 compared to chemotherapy in previously-treated metastatic pancreatic adenocarcinoma patients (ECLIPSE Study).

Le DT, Picozzi VJ, Ko AH, Wainberg ZA, Kindler H, Wang-Gillam A, Oberstein PE, Morse MA, Zeh H, Weekes CD, Reid T, Borazanci E, Crocenzi T, LoConte NK, Musher B, Laheru DA, Murphy A, Whiting C, Nair N, Enstrom A, Ferber S, Brockstedt DG, Jaffee EM.

Clin Cancer Res. 2019 May 24. pii: clincanres.2992.2018. doi: 10.1158/1078-0432.CCR-18-2992. [Epub ahead of print]

PMID:
31126960
2.

Experimental microdissection enables functional harmonisation of pancreatic cancer subtypes.

Maurer C, Holmstrom SR, He J, Laise P, Su T, Ahmed A, Hibshoosh H, Chabot JA, Oberstein PE, Sepulveda AR, Genkinger JM, Zhang J, Iuga AC, Bansal M, Califano A, Olive KP.

Gut. 2019 Jun;68(6):1034-1043. doi: 10.1136/gutjnl-2018-317706. Epub 2019 Jan 18.

PMID:
30658994
3.

Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness.

Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC.

Cancer Discov. 2018 Nov;8(11):1458-1473. doi: 10.1158/2159-8290.CD-18-0046. Epub 2018 Sep 5.

PMID:
30185628
4.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N.

Neuroendocrinology. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10.

PMID:
29991024
5.

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma.

Hingorani SR, Zheng L, Bullock AJ, Seery TE, Harris WP, Sigal DS, Braiteh F, Ritch PS, Zalupski MM, Bahary N, Oberstein PE, Wang-Gillam A, Wu W, Chondros D, Jiang P, Khelifa S, Pu J, Aldrich C, Hendifar AE.

J Clin Oncol. 2018 Feb 1;36(4):359-366. doi: 10.1200/JCO.2017.74.9564. Epub 2017 Dec 12.

PMID:
29232172
6.

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.

Yarchoan M, Myzak MC, Johnson BA 3rd, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.

Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.

7.

Current and Emerging Therapies in Metastatic Pancreatic Cancer.

Manji GA, Olive KP, Saenger YM, Oberstein P.

Clin Cancer Res. 2017 Apr 1;23(7):1670-1678. doi: 10.1158/1078-0432.CCR-16-2319. Review.

8.

Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma.

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, Dekleva EN, Saunders T, Becerra CP, Tattersall IW, Westphalen CB, Kitajewski J, Fernandez-Barrena MG, Fernandez-Zapico ME, Iacobuzio-Donahue C, Olive KP, Stanger BZ.

Cancer Cell. 2014 Jun 16;25(6):735-47. doi: 10.1016/j.ccr.2014.04.021. Epub 2014 May 22.

9.

Pancreatic cancer: why is it so hard to treat?

Oberstein PE, Olive KP.

Therap Adv Gastroenterol. 2013 Jul;6(4):321-37. doi: 10.1177/1756283X13478680.

10.

Uptake and patterns of use of gemcitabine for metastatic pancreatic cancer: a population-based study.

Oberstein PE, Hershman DL, Khanna LG, Chabot JA, Insel BJ, Neugut AI.

Cancer Invest. 2013 Jun;31(5):316-22. doi: 10.3109/07357907.2013.789904. Epub 2013 Apr 24.

PMID:
23614655
11.

Update on novel therapies for pancreatic neuroendocrine tumors.

Oberstein PE, Saif MW.

JOP. 2012 Jul 10;13(4):372-5. doi: 10.6092/1590-8577/964.

12.

Update on prognostic and predictive biomarkers for pancreatic neuroendocrine tumors.

Oberstein PE, Saif MW.

JOP. 2012 Jul 10;13(4):368-71. doi: 10.6092/1590-8577/965.

13.

Metastatic gastric large cell neuroendocrine carcinoma: a case report and review of literature.

Oberstein PE, Kenney B, Krishnamoorthy SK, Woo Y, Saif MW.

Clin Colorectal Cancer. 2012 Sep;11(3):218-23. doi: 10.1016/j.clcc.2012.01.005. Epub 2012 Mar 14. Review. No abstract available.

PMID:
22421002
14.

Pancreatic neuroendocrine tumors: entering a new era.

Oberstein PE, Remotti H, Saif MW, Libutti SK.

JOP. 2012 Mar 10;13(2):169-73. Review.

15.

Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.

Oberstein PE, Saif MW.

Clin Med Insights Oncol. 2012;6:41-51. doi: 10.4137/CMO.S7319. Epub 2012 Jan 4.

Supplemental Content

Loading ...
Support Center